05/22/2008 --
AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced that The Lancet, a peer-reviewed medical journal, will publish an article entitled, "
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial," in this week's May 24, 2008 issue. The article describes the results from AtheroGenics' 6,144-patient ARISE outcome trial of its novel diabetes drug candidate, AGI-1067.
"The ARISE trial has provided us with evidence that succinobucol may be a promising new therapy, based on clinical activity in a number of prespecified diabetes and cardiovascular endpoints... AtheroGenics' Press Release -
